107 related articles for article (PubMed ID: 22329665)
21. The cysteine-rich core domain of REIC/Dkk-3 is critical for its effect on monocyte differentiation and tumor regression.
Kinoshita R; Watanabe M; Huang P; Li SA; Sakaguchi M; Kumon H; Futami J
Oncol Rep; 2015 Jun; 33(6):2908-14. PubMed ID: 25823913
[TBL] [Abstract][Full Text] [Related]
22. REIC/Dkk-3 stable transfection reduces the malignant phenotype of mouse prostate cancer RM9 cells.
Chen J; Watanabe M; Huang P; Sakaguchi M; Ochiai K; Nasu Y; Ouchida M; Huh NH; Shimizu K; Kashiwakura Y; Kaku H; Kumon H
Int J Mol Med; 2009 Dec; 24(6):789-94. PubMed ID: 19885619
[TBL] [Abstract][Full Text] [Related]
23. Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer.
Uchida D; Shiraha H; Kato H; Nagahara T; Iwamuro M; Kataoka J; Horiguchi S; Watanabe M; Takaki A; Nouso K; Nasu Y; Yagi T; Kumon H; Yamamoto K
J Gastroenterol Hepatol; 2014 May; 29(5):973-83. PubMed ID: 24372695
[TBL] [Abstract][Full Text] [Related]
24. Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma.
Than SS; Kataoka K; Sakaguchi M; Murata H; Abarzua F; Taketa C; Du G; Yashiro M; Yanagihara K; Nasu Y; Kumon H; Huh NH
Oncol Rep; 2011 Apr; 25(4):989-95. PubMed ID: 21249317
[TBL] [Abstract][Full Text] [Related]
25. Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer.
Sawahara H; Shiraha H; Uchida D; Kato H; Nagahara T; Iwamuro M; Kataoka J; Horiguchi S; Watanabe M; Sakaguchi M; Takaki A; Nouso K; Nasu Y; Kumon H; Okada H
Cancer Gene Ther; 2016 Aug; 23(8):278-83. PubMed ID: 27468808
[TBL] [Abstract][Full Text] [Related]
26. Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer.
Nozaki I; Tsuji T; Iijima O; Ohmura Y; Andou A; Miyazaki M; Shimizu N; Namba M
Int J Oncol; 2001 Jul; 19(1):117-21. PubMed ID: 11408931
[TBL] [Abstract][Full Text] [Related]
27. Partial sensitization of human bladder cancer cells to a gene-therapeutic adenovirus carrying REIC/Dkk-3 by downregulation of BRPK/PINK1.
Jin Y; Murata H; Sakaguchi M; Kataoka K; Watanabe M; Nasu Y; Kumon H; Huh NH
Oncol Rep; 2012 Mar; 27(3):695-9. PubMed ID: 22076283
[TBL] [Abstract][Full Text] [Related]
28. Tumor suppressor REIC/DKK-3 and co-chaperone SGTA: Their interaction and roles in the androgen sensitivity.
Ochiai K; Morimatsu M; Kato Y; Ishiguro-Oonuma T; Udagawa C; Rungsuriyawiboon O; Azakami D; Michishita M; Ariyoshi Y; Ueki H; Nasu Y; Kumon H; Watanabe M; Omi T
Oncotarget; 2016 Jan; 7(3):3283-96. PubMed ID: 26658102
[TBL] [Abstract][Full Text] [Related]
29. A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines.
Tsuji T; Miyazaki M; Sakaguchi M; Inoue Y; Namba M
Biochem Biophys Res Commun; 2000 Feb; 268(1):20-4. PubMed ID: 10652205
[TBL] [Abstract][Full Text] [Related]
30. REIC/Dkk-3 induces cell death in human malignant glioma.
Mizobuchi Y; Matsuzaki K; Kuwayama K; Kitazato K; Mure H; Kageji T; Nagahiro S
Neuro Oncol; 2008 Jun; 10(3):244-53. PubMed ID: 18443132
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC/Dkk-3.
Tanimoto R; Sakaguchi M; Abarzua F; Kataoka K; Kurose K; Murata H; Nasu Y; Kumon H; Huh NH
Int J Cancer; 2010 Apr; 126(7):1562-9. PubMed ID: 19626590
[TBL] [Abstract][Full Text] [Related]
32. Canine REIC/Dkk-3 interacts with SGTA and restores androgen receptor signalling in androgen-independent prostate cancer cell lines.
Kato Y; Ochiai K; Kawakami S; Nakao N; Azakami D; Bonkobara M; Michishita M; Morimatsu M; Watanabe M; Omi T
BMC Vet Res; 2017 Jun; 13(1):170. PubMed ID: 28599655
[TBL] [Abstract][Full Text] [Related]
33. A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy.
Oka T; Kurozumi K; Shimazu Y; Ichikawa T; Ishida J; Otani Y; Shimizu T; Tomita Y; Sakaguchi M; Watanabe M; Nasu Y; Kumon H; Date I
Sci Rep; 2016 Sep; 6():33319. PubMed ID: 27625116
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation status of REIC/Dkk-3 gene in human malignancies.
Hayashi T; Asano H; Toyooka S; Tsukuda K; Soh J; Shien T; Taira N; Maki Y; Tanaka N; Doihara H; Nasu Y; Huh NH; Miyoshi S
J Cancer Res Clin Oncol; 2012 May; 138(5):799-809. PubMed ID: 22274868
[TBL] [Abstract][Full Text] [Related]
35. Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression.
Watanabe M; Kashiwakura Y; Huang P; Ochiai K; Futami J; Li SA; Takaoka M; Nasu Y; Sakaguchi M; Huh NH; Kumon H
Int J Oncol; 2009 Mar; 34(3):657-63. PubMed ID: 19212670
[TBL] [Abstract][Full Text] [Related]
36. The Downregulation of the Expression of CD147 by Tumor Suppressor REIC/Dkk-3, and Its Implication in Human Prostate Cancer Cell Growth Inhibition.
Mori A; Watanabe M; Sadahira T; Kobayashi Y; Ariyoshi Y; Ueki H; Wada K; Ochiai K; Li SA; Nasu Y
Acta Med Okayama; 2017 Apr; 71(2):135-142. PubMed ID: 28420895
[TBL] [Abstract][Full Text] [Related]
37. A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector.
Watanabe M; Sakaguchi M; Kinoshita R; Kaku H; Ariyoshi Y; Ueki H; Tanimoto R; Ebara S; Ochiai K; Futami J; Li SA; Huang P; Nasu Y; Huh NH; Kumon H
Oncol Rep; 2014 Mar; 31(3):1089-95. PubMed ID: 24398705
[TBL] [Abstract][Full Text] [Related]
38. REIC/Dkk-3 as a potential gene therapeutic agent against human testicular cancer.
Tanimoto R; Abarzua F; Sakaguchi M; Takaishi M; Nasu Y; Kumon H; Huh NH
Int J Mol Med; 2007 Mar; 19(3):363-8. PubMed ID: 17273781
[TBL] [Abstract][Full Text] [Related]
39. Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells.
Gohara Y; Tomonobu N; Kinoshita R; Futami J; Audebert L; Chen Y; Komalasari NLGY; Jiang F; Yoshizawa C; Murata H; Yamamoto KI; Watanabe M; Kumon H; Sakaguchi M
J Mol Med (Berl); 2023 Apr; 101(4):431-447. PubMed ID: 36869893
[TBL] [Abstract][Full Text] [Related]
40. Serum REIC/Dickkopf-3 Protein Level Predicts Disease-Free Survival in Patients with Hepatocellular Carcinoma.
Oyama A; Uchida D; Shiraha H; Sawahara H; Kato R; Iwamuro M; Horiguchi S; Okada H
Acta Med Okayama; 2020 Jun; 74(3):237-243. PubMed ID: 32577022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
